Clinical Trials Logo

Vaginal Atrophy clinical trials

View clinical trials related to Vaginal Atrophy.

Filter by:

NCT ID: NCT06391372 Not yet recruiting - Menopause Clinical Trials

Effect of Local Estriol Treatment Before Vaginal Repair Surgery

Start date: April 2024
Phase: Phase 3
Study type: Interventional

The aim of the study is to evaluate the effects of local estriol treatment applied before vaginal repair surgery on steroid receptors, inflammatory cell response, vascular, connective and nervous tissues in the vagina, and its effects on early postoperative period pelvic floor functions, satisfaction with the surgery and vaginal health.

NCT ID: NCT06353945 Not yet recruiting - Vaginal Atrophy Clinical Trials

Perceived Effectiveness of the Vaginal Moisturizer Investigational Product Under Normal Conditions of Use.

Start date: April 29, 2024
Phase: N/A
Study type: Interventional

The present research project aims to evaluate the perceived effectiveness of the product under investigation under normal conditions of use for 28 days, to defend the claims "High hydration power, relief of discomfort and improvement of vaginal tone."

NCT ID: NCT06207227 Completed - Vaginal Atrophy Clinical Trials

Clinical Performance and Safety of the VITA AV Clinical System

Start date: April 13, 2023
Phase: N/A
Study type: Interventional

The primary objective of this clinical investigation is to demonstrate that treatment with the VITA AV clinical system is feasible and to evaluate clinical performance and safety when used to improve the symptoms and signs of vaginal atrophy (VA) due to menopause.

NCT ID: NCT06136975 Completed - Vaginal Atrophy Clinical Trials

Low-level Laser Therapy for Genitourinary Syndromes and Stress Urinary Incontinence

Start date: September 30, 2022
Phase:
Study type: Observational

Genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) are common for women. Low-level laser therapy (LLLT) was applied for wound healing, but there was no study regarding treatment effect of GSM and SUI. This retrospective study aims to assess the efficacy of LLLT in alleviating GSM and SUI.

NCT ID: NCT06028009 Recruiting - Vaginal Atrophy Clinical Trials

PRP Injections for Genitourinary Syndrome of Menopause

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Platelet-rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. Injection of PRP stimulates cell growth and can has been proven safe and effective for uses in orthopedics, dermatology, and gynecology. Despite the relative paucity of data, the use of PRP as a therapy for sexual dysfunction and genitourinary symptoms in the setting of menopause has been patented as the O-Shot and V-Shot. This is a single-blinded randomized control trial to determine if PRP injections into the anterior vaginal wall improve sexual functioning in women diagnosed with the genitourinary syndrome of menopause (GSM) characterized by vaginal dryness/irritation.

NCT ID: NCT06000202 Recruiting - Vaginal Atrophy Clinical Trials

Elastographic Improvement of Vaginal Atrophy Treated by Erbium Yag Laser

Start date: August 21, 2023
Phase: N/A
Study type: Interventional

This study is a randomized controlled sham applied study. Its aim is to evaluate the efficacy of Er:YAG laser for the treatment of atrophic vaginitis in postmenopausal women. In this study, demonstration of the efficacy of Er:YAG laser for the treatment of atrophic vaginitis in postmenopausal women is intended with Maturation Index (MI), vaginal pH measurement, Female Sexual Function Index (FSFI), Vaginal Health Index (VaHI), Visual Analogue Scale (VAS) and ultrasonographic elastography

NCT ID: NCT05953090 Recruiting - Vaginal Atrophy Clinical Trials

VALOR: Vaginal Atrophy & Long-term Observation of Recovery

VALOR
Start date: October 30, 2023
Phase: N/A
Study type: Interventional

Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.

NCT ID: NCT05898191 Active, not recruiting - Clinical trials for Pelvic Floor Disorders

Effect of Laser Therapy on Vaginal Tissue

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Pelvic floor disorders, including prolapse, incontinence, and vulvovaginal atrophy decrease the quality of life of every fourth woman. Recent therapy including habits change, rehabilitation, surgery, or hormonal replacement is not possible in all patients. Laser therapy is currently being proposed as an alternative. Laser therapy was brought to the gynecological field from dermatology, where it is used for facial rejuvenation (wrinkles) and treatment of other skin abnormalities. In dermatology, the laser has proven its efficacy at the molecular and histological levels. However, this concept was brought to gynecology without comparable confirmation. The skin and vagina have a different structures, therefore effects of laser may differ. Patient satisfaction with the clinical effects of laser has been reported. However, based on recent reviews and sheep studies knowledge about histological and other effects is limited. The goal of this study is to gain knowledge about the histological, biomechanical effects and molecular effects of laser on vagina. Control samples were collected from women undergoing colporrhaphy. The laser group underwent laser treatment prior to the surgery. The gained knowledge may improve laser protocols and in the future maybe laser therapy will become standard treatment in urogynecology.

NCT ID: NCT05654610 Completed - Vaginal Atrophy Clinical Trials

Real-world Evidence Study on the Performance and Safety of Halova Ovules

Start date: March 1, 2022
Phase:
Study type: Observational

An open-label, multicentric, non-randomized, single-arm, pilot, interventional clinical investigation to confirm the tolerability and performance of the medical device Halova in lubrication of the vagina and vaginal atrophy treatment.

NCT ID: NCT05627791 Terminated - Vaginal Atrophy Clinical Trials

Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman

Start date: November 30, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Vulvovaginal atrophy affects around 90% of postmenopausal women who may present with symptoms such as dryness, irritation, itching, burning, and dyspareunia that negatively affect the quality of life. Topical estrogen is recommended for the treatment of vulvovaginal atrophy in postmenopausal women and the FDA approved it. But it may increase the risk of breast and endometrial cancer. The oxytocin hormone also promotes positive social behavior, stress regulation, and female sexual arousal. Many previous studies show that topical oxytocin is useful for reducing vaginal atrophy in postmenopausal women.